Deliver Your News to the World

Who’s Afraid of the Big Bad Flu? One company is diligently preparing for the worst case scenario with promising results. (AMEX:CVM)


BioMedReports, the news portal covering the biomedical news and financial sector in a special report about the H1N1 flu pandemic is reporting that CEL-SCI Corporation (AMEX: CVM) is positioned to help combat the virus after diligently preparing for the worst case scenario with promising results.

CEL-SCI’s preclinical studies have demonstrated that vaccines utilizing its proprietary L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology potentially induce protection against illnesses such as the swine influenza.

L.E.A.P.S. helps direct the immune response to the vaccine epitope.

“What this company’s technology proposes is the ability to attack what comes out of the Swine Flu’s mutations the moment it shows up, as opposed to what we have now,” reports M.E. Garza.

“The idea is very simple, if I’m looking for a bad guy and I know that bad guy is going to undergo facial reconstruction or hair color changes, the only way I’m going to be able to capture that bad guy is by focusing on parts of that person that cannot be changed,” explains CEL-SCI’s CEO, Geert Kersten.

While some companies like Novartis AG (NYSE:NVS), Sanofi-Aventis SA (NYSE:SNY), Baxter NYSE:BAX), Novavax, Inc. (NASDAQ:NVAX) and others are stockpiling vaccines and other treatments, that may not be enough.

The alarming new report appears today at

Biotech investors interested in accessing the complete database of clinical trials and upcoming FDA decisions can access that information on the same site:

Disclosure: No positions.


About BioMedReports.Com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.

For more biomedical sector and investment news, go to

Disclosure: No positions.

Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. BiomedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.


 FDA Calendar
 CEL-SCI Corporation

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.